Vor Biopharma announced the appointment of Nathan Jorgensen, PhD, as Chief Financial Officer. Dr. Jorgensen has over a decade of diverse experience in the financial industry focused on healthcare and biopharma at the Qatar Investment Authority (QIA), Calamos Investments and Stifel Nicolaus, as well as scientific doctoral and post-doctoral training. Dr. Jorgensen brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his new role at Vor. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private, and specialty investments. Prior to joining QIA, he led investments in therapeutics at Calamos, a growth-focused public equity investment firm with $25 billion of assets under management. Before joining Calamos, Dr. Jorgensen covered mid- and large-cap biotech companies at the investment bank Stifel Nicolaus.